Skip to main content
CHE logo

CHE · Chemed Corp

Track CHE — free
$532.88 -4.29 (-0.80%) At close · Aug 14
Market Cap
$6.96B
Shares
13.07M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$532.88 Open$535.27 Day$525.00–539.25 52W close$368.59–552.72 Avg vol 30d169K Short int461K · 3.5% float · 2.6d Short vol75% Last earningsJul 29, 2026 DataJan 2020–Aug 2026 Filing10-Q · Jul 31

Up next

Next earnings call
Oct 31, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed Jul 31, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Moderate
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg +21%
      above
      Price vs 50-day avg +9%
      above
      RSI (14) 59
      neutral
      MACD trend Negative
      52-week position 89%
      near high
      Volume (OBV) Bearish div.
      distributing
      Momentum
      relative strength
      Strong
      1-month return +4%
      trailing
      6-month return +11%
      trailing
      YTD return +25%
      this year
      Relative strength −2%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $488 › 200d $441 — 50d above 200d
      Institutional flow Accumulating
      +6% holders QoQ · +101 funds added
      Insider flow Distributing
      Net -$2.0M over 90 days · 100% sells
      Short interest Falling
      3.53% of float · ▼ -18.5% MoM · 2.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      522 holders — mid 3-yr range
      Squeeze score 52
      elevated · 0–100
      Fundamentals
      Strong
      Revenue growth +4%
      Y/Y
      EPS growth −8%
      Y/Y
      Free cash flow $325.5M
      Buyback $139.8M
      remaining
      Balance sheet $23.0M
      net debt
      Quant / Vol
      risk profile
      Moderate
      Volatility 29%
      annualized · 1-yr
      Max drawdown −23%
      past year
      ATR 2.6%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Apr 23, 2026
      2026
      ADC growth 4.5% – 5.5%
      Revenue growth, excluding the impact of the Medicare Cap 6.5% – 7.5%
      EBITDA margin, excluding the impact of the Medicare Cap 18% – 18.5%
      Adjusted earnings per diluted share Non-GAAP $24.00 – $24.75
      fiscal 2026
      Roto-Rooter revenue growth 3% – 3.5%
      Roto-Rooter adjusted EBITDA margin Non-GAAP 21.5% – 22.5%
      Prior guidance period ended · from the Earnings Call filed Dec 31, 2024
      VITAS revenue prior to Medicare cap · 2025 10.5% – 11.3%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Neutral
      2 · 2 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +21% Bullish
      Price vs 50-day avg
      +9% Bullish
      RSI (14)
      59 Neutral
      MACD trend
      Negative Bearish
      52-week position
      89% Bullish
      Volume (OBV)
      Bearish div. Bearish
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $488 › 200d $441 — 50d above 200d
      Institutional flow Accumulating
      +6% holders QoQ · +101 funds added
      Insider flow Distributing
      Net -$2.0M over 90 days · 100% sells
      Short interest Falling
      3.53% of float · ▼ -18.5% MoM · 2.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      522 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $369 Now $533 · 89% Range high $553
      vs 200-day avg +21% vs 50-day avg +9%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Medicare provider numbers with projected Cap cushion of 10% or greater 22 full-year 2026 (as of June 30, 2026)
      Net Income, excluding certain discrete items (Roto-Rooter) non-GAAP $33.8M second quarter of 2026
      Net Income, excluding certain discrete items (VITAS) non-GAAP $61.3M second quarter of 2026
      Adjusted EBITDA non-GAAP $53.5M first quarter of 2026
      Adjusted EBITDA margin non-GAAP 22.5% first quarter of 2026
      Net Income, excluding certain discrete items non-GAAP $52.2M first quarter of 2026
      Medicare Cap billing limitation accrued $2.4M the fourth quarter of 2025

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Medical Care Facilities — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      CHE
      Chemed Corp
      this stock
      $6.96B +24.5% +4.1% 3.5%
      HCA
      HCA Healthcare, Inc.
      $89.77B -13.3% +7.1% 13.9 2.7%
      FSNUY
      Fresenius SE & Co. KGaA
      $30.87B -4.4% 0.0%
      THC
      Tenet Healthcare Corp
      $21.57B +34.8% +0.9% 10.3 4.0%
      FMS
      Fresenius Medical Care AG
      $12.65B -0.2% +5.9% 0.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      522
      % held
      103.7%
      Net QoQ
      +356.7K sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      470
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      461.4K
      Days to cover
      2.6d
      Change
      -104.7K sh
      View
      Short Volume
      Short vol %
      75%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      12
      Value
      $5.2K
      As of
      Jun 17, 2026
      View
      Off-Exchange
      Off-exchange %
      37.6%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$2.0M
      Buyers / Sellers
      0 / 4
      Buyers Sellers
      View
      Congressional Trades Buy
      Member
      Lisa McClain
      Amount
      $1.0K–$15.0K
      Traded
      Jun 24, 2025
      View
      Financials
      Financials
      Revenue (FY)
      $2.5B
      Net income (FY)
      $265.2K
      EPS diluted
      $18.34
      View
      Buybacks
      Authorized
      $300.0M
      Remaining
      $139.8M
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      10-Q
      Filed
      Jul 31, 2026
      This year
      9
      View
      Proposed Sales
      Value
      $420.0K
      Shares
      1.0K
      Filed
      May 1, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jul 29, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      CHE -3.6% +4.5% +11.4% +0.1% +24.6%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY -4.0% +0.0% -2.4% -3.8% +10.7%

      Capital returns

      Latest dividend
      $0.60 / share · ex May 28, 2026
      Declared · upcoming
      $0.70 / share · ex Aug 17, 2026
      Raised 20%
      Paid (TTM)
      $1.80 / share · 3 payouts
      Dividend yield (TTM, derived)
      0.34%
      Buyback program · as of Jul 31, 2026
      Authorized
      $300.00M
      Spent (derived)
      $160.20M
      Remaining
      $139.80M
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 19584 CUSIP 16359R103 13F (30d) 509 filings 482 filers Visit website Investor relations